Search clinical trials for: Toripalimab Injection

Total 10155 results

Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
Zhejiang Genfleet Therapeutics Co., Ltd.

Withdrawn

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer | Clear Cell Renal Carcinoma

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor

China
Innolake Biopharm

Recruiting

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Melanoma | Soft Tissue Sarcoma | Cervical Cancer | Head and Neck Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Classic Hodgkin Lymphoma

China
LaNova Medicines Limited

Recruiting

Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Sun Yat-sen University

Recruiting

Chidamide Combined With Toripalimab in Sarcoma

Sarcoma

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Gastric Type Adenocarcinoma (GAS) With STK11 Mutation

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
First Affiliated Hospital of Zhejiang University

Recruiting

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Malignant Melanoma

China
Henan Cancer Hospital

Recruiting

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Perioperative Period

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Melanoma

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Xiangya Hospital of Central South University

Active, not recruiting

Thermal Ablation Followed by Immunotherapy for HCC

Hepatocellular Carcinoma Non-resectable

China
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
LaNova Australia Pty Limited

Terminated

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Sun Yat-sen University

Unknown

Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
West China Hospital

Recruiting

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Sun Yat-sen University

Unknown

Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy

Advanced Cancer | Small Cell Carcinoma of Esophagus

China
Ruijin Hospital
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

Carcinoma, Non-Small-Cell Lung

China
Maxinovel Pty., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor

China
LaNova Medicines Limited

Terminated

Study of LM-061 in Subjects in Advanced Tumors

Advanced Tumours

Australia
Sun Yat-sen University

Unknown

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Post-Operative Pain

Korea, Republic of
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery (SNMM)

Malignant Melanoma | Sinonasal Melanoma

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Lyvgen Biopharma Holdings Limited

Recruiting

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma

China
AnewPharma

Unknown

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung Cancer

China
Tianjin Medical University General Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Cervical Cancer | Cervix Cancer | Cervix Neoplasm

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Non-small Cell Lung Cancer | Second-line Treatment

China

3

Subscribe